Carlos Alfaras | President

Mr. Alfaras has served as President of Gensco Pharma since January of 2011. Since the acquisition, the company has launched three new products based on Patented Transdermal drug delivery technology and increased revenues by 2000% under his direction.

He was immersed into generic pharmaceutical distribution as teenager helping his grandfather and father’s company National Drug Wholesale (NDW), by working entry level jobs culminating in becoming the pharmaceutical buyer by high school graduation. NDW was acquired by Harvey Labs in 1987.

He attended the University of Miami, majoring in Biology/Pre-Medical studies and utilized this education and experience to enter the pharmaceutical management world.

In his dedication for the pursuit of excellence he has had successes in creating growth in revenues at every company he has been associated with through education, team building, strategic planning and efficiently determining the development strategies for all.

He has held the following positions:

  • Director of Purchasing and GM, PHARMED Group
  • Vice President, Sunshine Medical
  • C.O.O, DNA Pharmaceuticals
  • Head of Business Development, Bioniche Pharma
  • Senior Director Alternate Care and Business Development, ANDA Pharmaceuticals/ANDRX Corporation
  • Executive Director, Business Strategy, ANDA/Watson Pharmaceuticals
  • President & CEO, AHP Group
  • President, Gensco Pharma

Mr. Alfaras currently resides on the Board of Directors for the following companies:

  • AHP Group
  • FDA Consulting Group

He is also a member of the following non-profit organizations:

  • Catholic Charities
  • I9 Sports
  • Special Olympics International

Carlos Alfaras is dedicated to building a legacy of mentorship both professionally and personally and has been recognized as such by developing an ever-growing list of successful persons in the industry.

Return to Gensco Leadership Team Page »



A single dose topical colchinium for acute gout flares.


A single dose topical anesthetic for injections and vaccines.


Gensco® Pharma Partners with IntelGenx to Launch and Commercialize RIZAPORT® (Rizatriptin Oral Film) in the United States December 12, 2018 Featured, Industry, Press Release, Product Update - Miami, Florida, December 12, 2018 – Gensco® Pharma, a leading specialty pharmaceutical manufacturer specializing in development and commercialization of prescription more...

Looking To The Future

A single dose topical colchinium for acute gout flares.